Daymelis Santiesteban

Daymelis Santiesteban supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

Daymelis has special expertise in program evaluation of CMMI Accountable Care Organizations.

In her previous role at Avalere, Daymelis supported client work as a project accountant, managing project creation in the financial management system and collaborating with project managers to ensure accurate financial reporting. Prior to that, she was a sales auditor and accounting assistant at Stellar Partners.

Daymelis has an MA in public policy from George Mason University and a BA in international studies from the University of South Florida.

Authored Content

A new Avalere analysis examines the prevalence of utilization management (UM) in the commercial market from 2014 to 2020, focusing on drugs treating cancer, autoimmune diseases, and a range of other chronic conditions.

In September 2021, Avalere conducted an online survey of 51 US-based health plans and pharmacy benefit managers (PBMs), representing roughly 59 million covered lives. The survey indicates that 56% of payers have executed an outcomes-based contract (OBC) as of September 2021.

The Patient Centered Outcomes Research Institute (PCORI) recently announced an open comment period for a new set of proposed national priorities to inform its research agenda. Avalere analysis finds that from March 2019 to September 2020, PCORI directed roughly $259 million to comparative effectiveness research (CER) awards with an increasing share of new projects focused on drugs.

The US continues to face challenges with managing COVID-19 (SARS-CoV-2) while reopening communities. Accurate COVID-19 diagnostic testing is an effective tool in minimizing the risk of transmission.

New Avalere analysis finds higher premiums for the enhanced standalone drug plans participating in the model.

Health plans, including Medicare prescription drug plans, commonly apply utilization management (UM) tools to manage spending on prescription drugs.

Avalere analysis finds that new users account for a large share of Medicare spending on opthalmic medications.